Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 34 studies | 50% ± 21% | |
fibroblast | 11 studies | 28% ± 10% | |
microglial cell | 10 studies | 55% ± 25% | |
alveolar macrophage | 8 studies | 71% ± 32% | |
myeloid cell | 8 studies | 43% ± 18% | |
dendritic cell | 7 studies | 32% ± 12% | |
hepatocyte | 6 studies | 75% ± 28% | |
renal alpha-intercalated cell | 6 studies | 35% ± 6% | |
endothelial cell | 6 studies | 54% ± 20% | |
conventional dendritic cell | 6 studies | 27% ± 7% | |
monocyte | 5 studies | 44% ± 21% | |
erythroblast | 5 studies | 51% ± 8% | |
mast cell | 5 studies | 23% ± 6% | |
endothelial cell of sinusoid | 4 studies | 35% ± 12% | |
T cell | 4 studies | 39% ± 14% | |
myofibroblast cell | 4 studies | 27% ± 8% | |
smooth muscle cell | 4 studies | 19% ± 4% | |
pericyte | 4 studies | 21% ± 5% | |
type II pneumocyte | 4 studies | 37% ± 4% | |
hepatic stellate cell | 3 studies | 52% ± 27% | |
abnormal cell | 3 studies | 39% ± 25% | |
extravillous trophoblast | 3 studies | 36% ± 15% | |
capillary endothelial cell | 3 studies | 17% ± 0% | |
classical monocyte | 3 studies | 16% ± 1% | |
Mueller cell | 3 studies | 37% ± 12% | |
cholangiocyte | 3 studies | 56% ± 25% | |
inflammatory macrophage | 3 studies | 65% ± 8% | |
leukocyte | 3 studies | 22% ± 0% | |
erythrocyte | 3 studies | 56% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 131281.90 | 226 / 226 | 97% | 3198.54 | 394 / 406 |
lung | 98% | 4747.82 | 568 / 578 | 76% | 81.51 | 883 / 1155 |
brain | 69% | 3309.12 | 1814 / 2642 | 94% | 141.39 | 662 / 705 |
breast | 79% | 1344.60 | 362 / 459 | 75% | 61.20 | 843 / 1118 |
ovary | 63% | 690.90 | 113 / 180 | 71% | 57.56 | 306 / 430 |
adrenal gland | 100% | 28452.18 | 258 / 258 | 30% | 72.88 | 70 / 230 |
skin | 31% | 399.46 | 569 / 1809 | 82% | 163.75 | 386 / 472 |
thymus | 45% | 457.86 | 296 / 653 | 63% | 84.25 | 381 / 605 |
lymph node | 0% | 0 | 0 / 0 | 100% | 295.12 | 29 / 29 |
spleen | 100% | 3871.54 | 240 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 84% | 133.37 | 67 / 80 |
pancreas | 9% | 135.04 | 29 / 328 | 75% | 74.01 | 133 / 178 |
kidney | 8% | 54.65 | 7 / 89 | 75% | 125.95 | 673 / 901 |
intestine | 30% | 288.18 | 285 / 966 | 39% | 32.24 | 207 / 527 |
stomach | 9% | 57.23 | 34 / 359 | 57% | 57.55 | 162 / 286 |
uterus | 9% | 85.91 | 16 / 170 | 56% | 48.98 | 255 / 459 |
adipose | 56% | 778.28 | 677 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 51% | 53.86 | 23 / 45 |
bladder | 0% | 0 | 0 / 21 | 50% | 38.95 | 251 / 504 |
esophagus | 1% | 9.99 | 18 / 1445 | 39% | 26.76 | 72 / 183 |
prostate | 13% | 113.89 | 32 / 245 | 27% | 15.50 | 136 / 502 |
blood vessel | 16% | 515.24 | 218 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 14% | 464.61 | 130 / 929 | 0% | 0 | 0 / 0 |
muscle | 7% | 50.07 | 54 / 803 | 0% | 0 | 0 / 0 |
heart | 2% | 13.43 | 14 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0045833 | Biological process | negative regulation of lipid metabolic process |
GO_0034382 | Biological process | chylomicron remnant clearance |
GO_0034447 | Biological process | very-low-density lipoprotein particle clearance |
GO_0032374 | Biological process | regulation of cholesterol transport |
GO_0034369 | Biological process | plasma lipoprotein particle remodeling |
GO_0010916 | Biological process | negative regulation of very-low-density lipoprotein particle clearance |
GO_0008203 | Biological process | cholesterol metabolic process |
GO_0034379 | Biological process | very-low-density lipoprotein particle assembly |
GO_0033700 | Biological process | phospholipid efflux |
GO_0034375 | Biological process | high-density lipoprotein particle remodeling |
GO_0042157 | Biological process | lipoprotein metabolic process |
GO_0032375 | Biological process | negative regulation of cholesterol transport |
GO_0010900 | Biological process | negative regulation of phosphatidylcholine catabolic process |
GO_0006641 | Biological process | triglyceride metabolic process |
GO_0045717 | Biological process | negative regulation of fatty acid biosynthetic process |
GO_0050995 | Biological process | negative regulation of lipid catabolic process |
GO_0048261 | Biological process | negative regulation of receptor-mediated endocytosis |
GO_0033344 | Biological process | cholesterol efflux |
GO_0006629 | Biological process | lipid metabolic process |
GO_0051005 | Biological process | negative regulation of lipoprotein lipase activity |
GO_0042627 | Cellular component | chylomicron |
GO_0005576 | Cellular component | extracellular region |
GO_0034364 | Cellular component | high-density lipoprotein particle |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0034361 | Cellular component | very-low-density lipoprotein particle |
GO_0060228 | Molecular function | phosphatidylcholine-sterol O-acyltransferase activator activity |
GO_0055102 | Molecular function | lipase inhibitor activity |
GO_0031210 | Molecular function | phosphatidylcholine binding |
GO_0005504 | Molecular function | fatty acid binding |
GO_0004859 | Molecular function | phospholipase inhibitor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | APOC1 |
Protein name | Apolipoprotein C-I Apolipoprotein C1 Apolipoprotein C-I (Apo-CI) (ApoC-I) (Apolipoprotein C1) [Cleaved into: Truncated apolipoprotein C-I] |
Synonyms | |
Description | FUNCTION: Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein. . |
Accessions | K7EPR9 K7ERI9 K7EKP1 ENST00000588750.5 ENST00000592535.6 ENST00000592535 K7EJI9 K7ELU7 ENST00000592885.5 ENST00000592176.1 K7EPF9 ENST00000589781.1 ENST00000586638.5 K7ELM9 ENST00000590334.5 P02654 ENST00000588802.5 ENST00000589078.1 |